racecadotril has been researched along with Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V | 1 |
1 trial(s) available for racecadotril and Neutropenia
| Article | Year |
|---|---|
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan | 2000 |